...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Intestinal research. >Fecal immunochemical test as a biomarker for inflammatory bowel diseases: can it rival fecal calprotectin?
【24h】

Fecal immunochemical test as a biomarker for inflammatory bowel diseases: can it rival fecal calprotectin?

机译：粪便免疫化学测试可作为炎症性肠病的生物标志物：它可以与粪便钙卫蛋白竞争吗？

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Accurate evaluation of disease activity is essential for choosing an appropriate treatment and follow-up plan for patients with inflammatory bowel disease (IBD). Endoscopy is required for accurately evaluating disease activity, but the procedures are sometimes invasive and burdensome to patients. Therefore, alternative non-invasive methods for evaluating or predicting disease activity including mucosal status are desirable. Fecal calprotectin (Fcal) is the most widely used fecal marker for IBD, and many articles have described the performance of the marker in predicting disease activity, mucosal healing (MH), treatment efficacy, and risk of relapse. Fecal immunochemical test (FIT) can quantify the concentration of hemoglobin in stool and was originally used for the screening of colorectal cancer. We recently reported that FIT is also a useful biomarker for IBD. A direct comparison between the use of Fcal and FIT showed that both methods predicted MH in ulcerative colitis equally well. However, in the case of Crohn's disease, FIT was less sensitive to lesions in the small intestine, compared to Fcal. FIT holds several advantages over Fcal in regards to user-friendliness, including a lower cost, easy and clean handling, and the ability to make rapid measurements by using an automated measurement system. However, there is insufficient data to support the application of FIT in IBD. Further studies into the use of FIT for evaluating the inflammatory status of IBD are warranted.
机译：对炎症性肠病（IBD）患者选择正确的治疗和随访计划，准确评估疾病活动至关重要。内窥镜检查是准确评估疾病活动性所必需的，但是该过程有时具有侵入性并且给患者带来负担。因此，需要用于评估或预测包括粘膜状态在内的疾病活动的替代性非侵入性方法。粪钙卫蛋白（Fcal）是IBD使用最广泛的粪便标志物，许多文章都描述了该标志物在预测疾病活动，粘膜愈合（MH），治疗效果和复发风险中的作用。粪便免疫化学测试（FIT）可以量化粪便中血红蛋白的浓度，最初用于大肠癌的筛查。最近，我们报道FIT还是IBD的有用生物标志物。 Fcal和FIT的使用之间的直接比较表明，两种方法均可以很好地预测溃疡性结肠炎中的MH。但是，就克罗恩病而言，与Fcal相比，FIT对小肠病变的敏感性较低。就用户友好性而言，FIT与Fcal相比具有多个优势，包括成本更低，易于清洁的操作以及使用自动化测量系统进行快速测量的能力。但是，没有足够的数据来支持FIT在IBD中的应用。有必要进一步研究使用FIT评估IBD的炎症状态。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号